Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

Table of Contents

 


SUMMARY FINANCIAL DATA

        The following summary financial data for the years ended December 31, 2012 and 2013 have been derived from our audited financial statements included elsewhere in this prospectus. The selected statement of operations data for the six months ended June 30, 2013 and 2014 and the selected balance sheet data as of June 30, 2014 were derived from our unaudited financial statements appearing elsewhere in this prospectus. These unaudited financial statements have been prepared on a basis consistent with our financial statements and, in our opinion, contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. You should read this data together with our audited financial statements and related notes included elsewhere in this prospectus and the information under the captions "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Our historical results are not necessarily indicative of our future results, and our operating results for the six-month period ended June 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014 or any other interim periods or any future year or period.

 
  Proteon Therapeutics, Inc.  
 
  Years Ended
December 31,
  Six Months Ended
June 30,
 
 
  2012   2013   2013   2014  
 
   
   
  (Unaudited)
 
 
  (in thousands except share and per share data)
 

Operating expenses:

                         

Research and development

  $ 5,907   $ 3,994   $ 2,003   $ 2,785  

General and administrative

    2,089     3,128     1,417     1,656  

Acquired in-process research and development

                 
                   

Total operating expenses

    7,996     7,122     3,420     4,441  
                   

Loss from operations

    (7,996 )   (7,122 )   (3,420 )   (4,441 )

Other income (expense):

                         

Investment income

    20     4     3     3  

Interest expense

        (861 )       (857 )

Other income (expense)

    6     67     5     (99 )
                   

Total other income (expense)

    26     (790 )   8     (953 )
                   

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )
                   
                   

Unrealized loss on available-for-sale investments

    (5 )   (1 )       (23 )
                   

Comprehensive loss

  $ (7,975 ) $ (7,913 ) $ (3,412 ) $ (5,417 )
                   
                   

Reconciliation of net loss to net loss attributable to common stockholders

                         

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )

Accretion of redeemable convertible preferred stock to redemption value

    (6,133 )   (6,119 )   (3,039 )   (3,409 )

Extinguishment of Series B redeemable convertible preferred stock

                 
                   

Net loss attributable to common stockholders

  $ (14,103 ) $ (14,031 ) $ (6,451 ) $ (8,803 )
                   
                   

Net loss per share attributable to common stockholders—basic and diluted

  $ (3.85 ) $ (3.76 ) $ (1.76 ) $ (2.31 )
                   
                   

Weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted

    3,659,790     3,732,436     3,659,790     3,812,904  
                   
                   

Pro forma net loss per share attributable to common stockholders—basic and diluted (unaudited)

        $ (0.10 )       $ (0.04 )
                       
                       

Pro forma weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted (unaudited)

          72,457,068           107,333,127  
                       
                       

 

10